Enhancement of cell cycle inhibition effect of cetuximab by using stabilized-silver solution in lung cancer cells

JOINT EVENT:19^th Euro Congress on Cancer Science and Therapy & 25^th Cancer Nursing & Nurse Practitioners Conference

July 17-19, 2017 Lisbon, Portugal

Aysun Ozkan and Ayse Erdogan

Akdeniz University, Turkey

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

This study aimed to evaluate the expression levels of topoisomerase alpha and cyclin1 and 2 in parental (P-H1299) and epirubicin resistant (R-H1299) lung cancer cells. These cells were treated with cetuximab (C225, Erbitux, a chimeric anti-epidermal growth factor receptor (EGFR) monoclonal antibody) alone and combined with stabilized-silver (St-Ag) ion solution. Total cellular RNA was isolated by RNeasy mini kit (Qiagen) after cetuximab alone and combined with St-Ag ion solution treatment for 72 hours. Total RNA was reverse-transcribed into cDNA by using Titan One Tube RT-PCR system kit. Two �¼l of the cDNA was used for the PCR reaction as templates. The PCR was performed in 30 cycles of denaturation at 94�ºC for 1 min, annealing at 55�ºC for 1 min and extension at 72�ºC for 2 min. The resulting PCR products were analyzed by 2.5% agarose gel electrophoresis. Adobe photoshop CS4 program was used for band density analyzing. Cetuximab with St-Ag ion solution treatment was found more effective than cetuximab alone treatment in decreasing topoisomerase alpha (except in R-H1299 cells) and cyclin1 and 2 expressions in both cells according to control cells. Combine treatment caused more arrest in G1-phase of the cell cycle in these cells. In this study, we demonstrated that cetuximab alone and combine with St-Ag ion solution could exhibit potent anticancer activity by arresting the cell cycle in lung cancer cells. Our study may provide a reason for future clinical investigations of cetuximab combination therapy for growth control of lung cancer.

Biography :

Email: aozkan@akdeniz.edu.tr